Small molecule · Modulator of estrogen receptor alpha (ESR1) and estrogen receptor beta (ESR2) · developed by Ligand Pharmaceuticals
Lasofoxifene is a non-steroidal, third-generation selective estrogen receptor modulator that binds estrogen receptor alpha and beta with high affinity, acting as an agonist in some tissues and an antagonist in others.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00141323 | Phase 3 | Osteoporosis | Completed | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Osteoporosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.
See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGND catalysts and pipeline →